Biosimilar Fights Regeneron Bid To Block Eye Treatment
A specialist in biosimilar medicine has pushed back against Regeneron's requests for an injunction, arguing that forcing it to destroy its biosimilar version of a blockbuster eye medicine would be "inappropriate"...To view the full article, register now.
Already a subscriber? Click here to view full article